– LentiGlobin in transfusion-dependent β-thalassemia (TDT) planned to be filed for marketing authorization in 2018 – – bb2121 in relapsed/refractory multiple myeloma planned to be filed for marketing ...
bluebird bio (NASDAQ: BLUE) reported fourth-quarter earnings after the closing bell on Wednesday. Without any products on the market, the quarterly pipeline update is more important than the revenue ...
As the chart shows, the stock price benefited from three large jumps in June, August, and December. Here's how it went down. In June, at the annual American Society of Clinical Oncology (ASCO) meeting ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T ...
Clinical-stage gene therapy specialist bluebird bio (NASDAQ: BLUE) reported second-quarter earnings last week, which mostly just served as a reminder of its pipeline progress because revenue and ...
As the chart shows, the stock price benefited from three large jumps in June, August, and December. Here's how it went down. bb2121 is part of a new class of therapies called chimeric antigen receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results